Treatment of meningoencephalitis of unknown origin in a dog

Behr, S.; Llabrés-Días, F. J. L.; Radaelli, S. T.
May 2009
Veterinary Record: Journal of the British Veterinary Association;5/16/2009, Vol. 164 Issue 20, p627
Academic Journal
The article focuses on the efficacy of immunosuppressive agents in managing a relapse of meningoencephalitis of unknown origin (MUO) in dogs. It says that MUO is one of the causes of inflammatory central nervous system disease that occurs in dogs. Agents such as prednisolone and cytosine arabinoside were given to dogs and showed no sign of relapse and a gradual improvement was observed in dogs. It notes that phenobarbitone and ciclosporin help control the clinical signs of MUO relapse.


Related Articles

  • Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Trial. Hiemstra, Thomas F.; Walsh, Michael; Mahr, Alfred; Savage, Caroline O.; de Groot, Kirsten; Harper, Lorraine; Hauser, Thomas; Neumann, Irmgard; Tesar, Vladimir; Wissing, Karl-Martin; Pagnoux, Christian; Schmitt, Wilhelm; Jayne, David R. W. // JAMA: Journal of the American Medical Association;12/1/2010, Vol. 304 Issue 21, p2381 

    The article focuses on an open-label randomized controlled trial which compared the effects of mycophenolate mofetil with azathioprine on the prevention of relapses in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAC). The study was conducted from April 2002...

  • Fingolimod (Gilenya): How far will it go to treat MS?  // Momentum (19403410);Winter2010/2011, Vol. 4 Issue 1, p57 

    The article offers information on fingolimod, the first oral disease-modifying drug to treat relapsing multiple sclerosis (MS) that was approved by the U.S. Food and Drug Administration. Fingolimod goes by the brand name Gilenya. As of December 2010, research on fingolimod still continues in...

  • The challenges that clinicians and patients face when selecting first-line treatments for multiple sclerosis. Barker, Noreen // British Journal of Neuroscience Nursing;Dec2013/Jan2014, Vol. 9 Issue 6, p267 

    Over the past 12 years the treatments available to people with the relapsing-remitting form of multiple sclerosis (MS) have changed dramatically, with the introduction of the disease-modifying therapies (beta-interferons and glatiramer acetate). For clinicians the challenge is to select the most...

  • Dimethyl Fumarate: A Review in Relapsing-Remitting MS. Deeks, Emma // Drugs;Feb2016, Vol. 76 Issue 2, p243 

    Dimethyl fumarate (Tecfidera) is an oral disease-modifying agent indicated for the twice-daily treatment of relapsing forms of multiple sclerosis (MS) and relapsing-remitting MS (RRMS). It displays immunomodulating and neuroprotective properties, both of which may contribute to its efficacy in...

  • FDA Actions. Elliott, William T. // Clinical Oncology Alert;Nov2010 Supplement, p2 

    The article presents updates on actions taken by the U.S. Food and Drug Administration (FDA) as of November 2010. Fingolimod has been approved by the FDA for reducing relapses and delay disability progression in patients with relapsing-remitting multiple sclerosis. Approval of lorcaserin...

  • Therapy of NMO spectrum disorders. Biswas, Atanu; Mukherjee, Arabinda // Annals of Indian Academy of Neurology;2015 Supplement, Vol. 18, pS16 

    Neuromyelitis optica (NMO) is an autoimmune demyelinating condition of the central nervous system often associated with aquaporin-4 (AQP4) autoantibodies manifesting as severe optic neuritis and long segment myelitis with tendency to relapse. Seronegative patients and who do not meet the NMO...

  • Ciclosporin.  // Reactions Weekly;2/6/2010, Issue 1287, p12 

    The article describes the case of a 51-year-old female patient who experienced chronic generalized periodontitis after taking ciclosporin.

  • Tacrolimus monotherapy may potentially reduce corticosteroid use in uveitis patients.  // Ocular Surgery News;8/25/2012, Vol. 30 Issue 16, p12 

    No abstract available.

  • FDA actions. Elliott, William T. // Critical Care Alert;Dec2010 Pharmacology, p2 

    The article offers information on the actions taken by the U.S. Food and Drug Administration (FDA), including the approval of fingolimod as treatment for multiple sclerosis' relapsing forms, labeling change order for bisphosphonates, and approval of dabigatran for blood clots and stroke...


Read the Article


Sign out of this library

Other Topics